Outsourcing-Pharma: SRI teams up with ShangPharma to target Alzheimer’s

“ShangPharma Innovation and SRI International are collaborating to develop treatments for neurodegenerative and inflammatory conditions, such as Alzheimer’s disease.

Under the agreement, SRI will provide target specific mechanistic assays for screening and ShangPharma Innovation (SPII) will provide in vivo models, to develop enzyme inhibitors that target brain inflammation.”

Media Inquiries

Heidi Chokeir, Ph.D.
Canale Communications
[email protected]